CCO Oncology Podcast

Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management

Episode Summary

In this podcast episode, experts discuss navigating therapy selection for patients with advanced hepatocellular carcinoma throughout lines of therapy. They describe which factors they consider in the absence of clinical trial data and the role of real-world evidence to support treatment decisions.

Episode Notes

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:

• Factors to consider before selecting frontline immunotherapy
• Role of TKIs in the frontline
• Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy
• Real-world evidence on frontline immunotherapy/VEGF combination therapy
• Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy

Presenters:

Heinz-Josef Klumpen, MD, PhD
Staff Specialist, Medical Oncologist
Department of Medical Oncology
Amsterdam UMC
Amsterdam, The Netherlands

Chris Verslype, MD, PhD
Professor
Clinical Digestive Oncology
KULeuven
Head of Clinic
Hepatology
Digestive Oncology
U.Z. Leuven
Leuven, Belgium